REVENUES (Tables)

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenues

The following table summarizes our Total revenues:

	Three Months Ended September 30, 2022								Three Months Ended September 30, 2021
(in millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product sales:
HIV
Biktarvy	$	2,286	$	278	$	201	$	2,766	$	1,875	$	254	$	147	$	2,276
Complera/Eviplera	20		21		3		43		28		31		5		64
Descovy	444		28		28		500		355		42		36		433
Genvoya	502		71		27		600		576		100		68		744
Odefsey	276		86		12		374		275		112		12		399
Stribild	22		7		3		32		28		11		3		42
Truvada	24		3		2		30		55		5		7		67
Revenue share - Symtuza(1)	85		40		4		130		86		41		3		130
Other HIV(2)	1		6		5		12		24		6		4		34
Total HIV	3,661		541		285		4,487		3,302		602		285		4,189
Veklury	336		130		458		925		1,527		109		287		1,923
Hepatitis C virus (“HCV”)
Ledipasvir/Sofosbuvir(3)	8		5		12		25		14		5		26		45
Sofosbuvir/Velpatasvir(4)	241		131		84		455		173		77		82		332
Other HCV(5)	34		7		2		44		37		12		3		52
Total HCV	283		143		98		524		224		94		111		429
Hepatitis B virus (“HBV”) / Hepatitis delta virus (“HDV”)
Vemlidy	129		9		90		228		103		9		96		208
Viread	2		5		15		22		1		7		18		26
Other HBV/HDV(6)	—		13		—		14		—		13		—		13
Total HBV/HDV	131		28		106		264		104		29		114		247
Cell therapy
Tecartus	60		20		1		81		35		12		—		47
Yescarta	210		91		16		317		100		66		9		175
Total cell therapy	270		111		17		398		135		78		9		222
Trodelvy	139		38		3		180		100		1		—		101
Other
AmBisome	9		63		33		105		7		67		69		143
Letairis	43		—		—		43		46		—		—		46
Other(7)	28		11		13		52		34		17		5		56
Total other	80		75		46		200		87		84		74		245
Total product sales	4,900		1,064		1,013		6,978		5,479		997		880		7,356
Royalty, contract and other revenues	28		37		—		64		30		34		1		65
Total revenues	$	4,928	$	1,101	$	1,013	$	7,042	$	5,509	$	1,031	$	881	$	7,421

	Nine Months Ended September 30, 2022								Nine Months Ended September 30, 2021
(in millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product sales:
HIV
Biktarvy	$	6,088	$	807	$	577	$	7,472	$	4,926	$	707	$	461	$	6,094
Complera/Eviplera	56		76		10		142		73		104		12		189
Descovy	1,152		92		91		1,335		994		128		105		1,227
Genvoya	1,441		220		103		1,764		1,633		306		184		2,123
Odefsey	763		278		36		1,077		773		336		39		1,148
Stribild	68		23		7		98		94		33		12		139
Truvada	77		12		13		102		268		18		24		310
Revenue share - Symtuza(1)	251		126		10		388		261		125		8		394
Other HIV(2)	11		20		15		45		110		19		24		153
Total HIV	9,906		1,653		863		12,422		9,132		1,776		869		11,777
Veklury	1,179		560		1,166		2,905		2,763		761		684		4,208
HCV
Ledipasvir/Sofosbuvir(3)	27		13		43		83		63		24		76		163
Sofosbuvir/Velpatasvir(4)	629		288		244		1,161		649		234		272		1,155
Other HCV(5)	88		31		7		127		97		64		9		170
Total HCV	745		332		294		1,371		809		322		357		1,488
HBV/HDV
Vemlidy	306		27		289		622		266		25		298		589
Viread	4		17		48		69		8		22		55		85
Other HBV/HDV(6)	1		41		—		42		1		29		—		30
Total HBV/HDV	311		85		337		733		275		76		353		704
Cell therapy
Tecartus	160		56		2		217		94		25		—		119
Yescarta	528		253		42		823		300		188		25		513
Total cell therapy	688		308		44		1,040		394		213		25		632
Trodelvy	379		98		8		485		261		1		—		262
Other
AmBisome	48		192		140		380		32		202		186		420
Letairis	135		—		—		135		157		—		—		157
Other(7)	91		52		35		178		109		68		23		200
Total other	275		244		174		693		298		270		209		777
Total product sales	13,482		3,281		2,887		19,650		13,932		3,419		2,497		19,848
Royalty, contract and other revenues	140		98		4		242		70		140		3		213
Total revenues	$	13,622	$	3,378	$	2,891	$	19,892	$	14,002	$	3,559	$	2,500	$	20,061

_______________________________

(1)     Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).

(2)     Includes Atripla, Emtriva and Tybost.

(3)     Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.

(4)     Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.

(5)     Includes Vosevi and Sovaldi.

(6)     Includes Hepcludex and Hepsera.

(7)     Includes Cayston, Jyseleca, Ranexa and Zydelig.

Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(as a percentage of total revenues)	2022		2021		2022		2021
AmerisourceBergen Corporation	18	%	25	%	17	%	24	%
Cardinal Health, Inc.	25	%	22	%	25	%	21	%
McKesson Corporation	22	%	21	%	20	%	18	%

Revenues Recognized from Performance Obligations Satisfied in Prior Periods

The following table summarizes revenues recognized from performance obligations satisfied in prior periods:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(in millions)	2022		2021		2022		2021
Revenue share with Janssen and royalties for licenses of intellectual property	$	192	$	190	$	573	$	625
Changes in estimates	$	207	$	188	$	452	$	661